Search hospitals > California > Novato
Sutter Cancer Research Consortium
Claim this profileNovato, California 94945
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Recurrence
Conducts research for Adenocarcinoma
132 reported clinical trials
6 medical researchers
Summary
Sutter Cancer Research Consortium is a medical facility located in Novato, California. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Recurrence, Adenocarcinoma and other specialties. Sutter Cancer Research Consortium is involved with conducting 132 clinical trials across 304 conditions. There are 6 research doctors associated with this hospital, such as Ari Baron, MD, Deepti Behl, Kristie A. Bobolis, and Edmund W. Tai.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 negative
ER positive
PR positive
Top PIs
Ari Baron, MDAlta Bates Summit Medical Center-Herrick Campus7 years of reported clinical research
Expert in Cancer
Studies Lung Cancer
28 reported clinical trials
66 drugs studied
Deepti BehlCalifornia Pacific Medical Center-Pacific Campus4 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
16 reported clinical trials
49 drugs studied
Kristie A. BobolisAlta Bates Summit Medical Center-Herrick Campus1 year of reported clinical research
Studies Breast Cancer
Studies Cancer
10 reported clinical trials
27 drugs studied
Edmund W. TaiAlta Bates Summit Medical Center-Herrick Campus9 years of reported clinical research
Studies Cancer
Studies Lung Cancer
7 reported clinical trials
37 drugs studied
Clinical Trials running at Sutter Cancer Research Consortium
Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Multiple Myeloma
Ovarian Cancer
Fallopian Tube Cancer
Peritoneal Cancer
Renal Cell Carcinoma
Meningioma
Cancer
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Chemotherapy Reduction After Surgery
for Breast Cancer
This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Trastuzumab and pertuzumab are both a form of "targeted therapy" because they work by attaching themselves to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When these drugs attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving paclitaxel, trastuzumab, and pertuzumab may enable fewer chemotherapy drugs to be given without compromising patient outcomes compared to the usual treatment.
Recruiting1 award Phase 227 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Sutter Cancer Research Consortium?
Sutter Cancer Research Consortium is a medical facility located in Novato, California. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Recurrence, Adenocarcinoma and other specialties. Sutter Cancer Research Consortium is involved with conducting 132 clinical trials across 304 conditions. There are 6 research doctors associated with this hospital, such as Ari Baron, MD, Deepti Behl, Kristie A. Bobolis, and Edmund W. Tai.